Rafael Perera News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rafael perera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rafael Perera Today - Breaking & Trending Today
Félix Navarro y el "estado de derecho" en Cuba cubanet.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cubanet.org Daily Mail and Mail on Sunday newspapers.
The AstraZeneca-Oxford COVID-19 vaccine is associated with some increases in bleeding and clotting events, according to a BMJ study yesterday, but experts say the benefits outweigh the risks. The researchers compared 28-day post-vaccination comorbidities in 291,264 Danish and Norwegian adults under 65 with the general population. Most (79.0%) were women, with a median age for all patients of 44 to 45. People who had experienced any adverse events in the past year were excluded. The results show no association between arterial events and COVID vaccination, but the risk of venous thromboembolism was increased 1.97-fold, though to only 11 excess occurrences per 100,000 vaccinations. Cerebral venous thromboembolisms in particular increased 20.25-fold, resulting in 2.5 excess occurrences per 100,000 vaccinations. A ....
›New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events low New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events low SECTIONS New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events lowPTI Last Updated: May 07, 2021, 05:35 PM IST Share Synopsis The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca vaccine. iStock Related NEW DELHI: A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population. However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse ....
Study assesses the rate of rare blood clots in adults receiving Oxford-AstraZeneca vaccine A large study from Denmark and Norway published by The BMJ today sheds more light on the risk of rare blood clots in adults receiving their first dose of the Oxford-AstraZeneca covid-19 vaccine. The findings show slightly increased rates of vein blood clots including clots in the veins of the brain, compared with expected rates in the general population. However, the researchers stress that the risk of such adverse events is considered low. Cases of rare blood clots in people who have recently received their first dose of the Oxford-AstraZeneca covid-19 vaccine have been reported. Whether these cases represent excess events above expected rates in the general population has, however, been debated. ....
The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine, known as Covishield in India, from February 2021 through to 11 March 2021 in Denmark and Norway. Using national health records, they identified rates of events, such as heart attacks, strokes, deep vein blood clots and bleeding events within 28 days of receiving a first vaccine dose and The researchers found 59 blood clots in the veins compared with 30 expected, corresponding to 11 excess events per 100,000 vaccinations. This included a higher than expected rate of blood clots in the veins of the brain, known as cerebral venous thrombosis (2.5 events per 100,000 vaccinations), the said. ....